Skip to main content

Table 2 Patient demographics and sample characteristics

From: Impact of molecular subtypes on the prediction of distant recurrence in estrogen receptor (ER) positive, human epidermal growth factor receptor 2 (HER2) negative breast cancer upon five years of endocrine therapy

Age [years]

 Min

37.7

 

 P25%

55.7

 

 Median

62.46

 

 P75%

69.3

 

 Max

83.5

 
 

N

%

Menopausal status

 Premenopausal

32

9.9

 Perimenopausal

6

1.9

 Postmenopausal

258

80.1

 NA

26

8.1

Breast-conserving surgery

 Yes

279

86.6

 No

43

13.4

Histological subtype

 Invasive ductal

243

75.5

 Invasive lobular

63

19.6

 Tubular

7

2.2

 Mucinous

5

1.6

 Others

4

1.2

Tumor grading

 G1

83

25.8

 G2

224

69.6

 G3

15

4.7

T-stage

 pT 1a

5

1.6

 pT 1b

72

22.4

 pT 1c

185

57.5

 pT 2

56

17.4

 pT 3

4

1.2

N-stage

 pN 0

278

86.3

 pN 1mic

13

4

 pN 1a

25

7.8

 pN 2a

2

0.6

 pN 3a

3

0.9

 NA

1

0.3